Search

Displaying results 2061 - 2070 of 5419 in total
  1. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    [A187361] While dual corrector/potentiator combination therapy has proven useful in the treatment of a subset of CF patients,[A187358] their use is typically limited to patients who are homozygous for … [A187361] The triple combination product Trikafta<sup>TM</sup>, manufactured by Vertex Pharmaceuticals, is the first product approved for the treatment of CF in individuals who are either homo- _or_ heterozygous

  2. Drug

    Seproxetine

    go.drugbank.com/drugs/DB06731
    Experimental

    Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.

  3. Drug

    Ferric sulfate

    go.drugbank.com/drugs/DB11171
    Approved

    It is produced by the reaction of sulfuric acid and an oxidizing agent. … [A32355, A32356] By the FDA, ferric sulfate is a direct food substance affirmed in the GRAS category (Generally Recognized As Safe).[L2003]

  4. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase … The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor.

  5. Drug

    Minocycline

    go.drugbank.com/drugs/DB01017
    ApprovedInvestigational

    Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifi...

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Eteplirsen

    go.drugbank.com/drugs/DB06014
    ApprovedInvestigational

    Eteplirsen was the first treatment for DMD approved by the FDA.[A244925] … [L40015] Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and premature death most commonly due to respiratory or cardiac complications.

  7. Drug

    Autologous cultured chondrocytes

    go.drugbank.com/drugs/DB10997
    ApprovedInvestigational

    The surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis.

  8. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … the FDA as treatments for retinal diseases; Enzeevi (aflibercept-abzv)[L53053], approved in August 2024, was also approved by the FDA for similar indications.

  9. Drug

    Eszopiclone

    go.drugbank.com/drugs/DB00402
    ApprovedInvestigational

    Eszopiclone was initially approved by the FDA in 2004.[L6769] … One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia.

  10. Drug

    Lovastatin

    go.drugbank.com/drugs/DB00227
    ApprovedInvestigational

    [A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality. … [A181087, A181406] Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease